Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14143340
Abstract: Simple Summary By combining drug screens, transcriptomic studies, and in vitro assays, our study identified the natural product toyocamycin as a potent and selective CDK9 inhibitor. Thus, toyocamycin can be used as a new small… read more here.
Keywords: cdk9 inhibition; cancer cells; cancer; selective cdk9 ... See more keywords